Abstract
Farnesoid X receptor (FXR, NR1H4), a nuclear receptor (NR) highly expressed in the liver, intestine, kidney, adrenal glands and other cholesterol-rich tissues, functions as the master regulator for bile acid homeostasis. FXR, which regulates the expression of genes encoding proteins involved in cholesterol homeostasis, plays an essential role in regulating cholesterol, lipid, and glucose metabolism. Recently, some FXR agonists are reported to have low selectivity on NRs, which forces the researchers to move their eyes onto the development of FXR antagonists with high selectivity. The development of non-steroidal FXR antagonists with different scaffolds including AGN34, tuberatolides, atractylenolides, andrographolides, GW4064 derivatives and 1,3,4-trisubstitutedpyrazolones, provides us a prospect for the therapy of in ammation, metabolic syndrome, diabetes, cholesterol gallstones, and cancer.
Keywords: Cholestasis, Farnesoid-x-receptor, Non-steroidal antagonist, Pharmacological target.
Current Topics in Medicinal Chemistry
Title:Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications
Volume: 14 Issue: 19
Author(s): Huang Huang, Yong Xu, Jin Zhu and Jian Li
Affiliation:
Keywords: Cholestasis, Farnesoid-x-receptor, Non-steroidal antagonist, Pharmacological target.
Abstract: Farnesoid X receptor (FXR, NR1H4), a nuclear receptor (NR) highly expressed in the liver, intestine, kidney, adrenal glands and other cholesterol-rich tissues, functions as the master regulator for bile acid homeostasis. FXR, which regulates the expression of genes encoding proteins involved in cholesterol homeostasis, plays an essential role in regulating cholesterol, lipid, and glucose metabolism. Recently, some FXR agonists are reported to have low selectivity on NRs, which forces the researchers to move their eyes onto the development of FXR antagonists with high selectivity. The development of non-steroidal FXR antagonists with different scaffolds including AGN34, tuberatolides, atractylenolides, andrographolides, GW4064 derivatives and 1,3,4-trisubstitutedpyrazolones, provides us a prospect for the therapy of in ammation, metabolic syndrome, diabetes, cholesterol gallstones, and cancer.
Export Options
About this article
Cite this article as:
Huang Huang, Xu Yong, Zhu Jin and Li Jian, Recent Advances in Non-Steroidal FXR Antagonists Development for Therapeutic Applications, Current Topics in Medicinal Chemistry 2014; 14 (19) . https://dx.doi.org/10.2174/1568026614666141112101840
DOI https://dx.doi.org/10.2174/1568026614666141112101840 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Orofacial Pain and Mastication in Dementia
Current Alzheimer Research <i>In-Silico</i> and <i>In-Vitro</i> Analysis of Human <i>SOS1</i> Protein Causing Noonan Syndrome - A Novel Approach to Explore the Molecular Pathways
Current Genomics Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry The Gut Microbiome
Inflammation & Allergy - Drug Targets (Discontinued) Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Processing of DNA Replication and Repair Intermediates by the Concerted Action of RecQ Helicases and Rad2 Structure-Specific Nucleases
Protein & Peptide Letters Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Cancellers - Exploring the Possibility of Receptor Decoy Traps As a Superior Anti-Retroviral Strategy
Current Drug Targets Regulation of Matrix Synthesis, Remodeling and Accumulation in Glomerulosclerosis
Current Pharmaceutical Design Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Matrix Metalloproteinases
Current Medicinal Chemistry microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA